Siemens Applauded by Frost & Sullivan for Supporting the Evolution of Smart Hospitals and Its Market-leading Position
Siemens strengthens its leadership position in the healthcare sector with its competency…
ELLKAY Names Ajay Kapare CEO
Longtime healthcare leader steps into CEO role to propel the company's next…
Bristol Myers Squibb Presents Results from CheckMate -8HW Analysis Evaluating Opdivo (nivolumab) plus Yervoy (ipilimumab) Compared to Opdivo Monotherapy…
Patients experienced a 38% reduction in the risk of disease progression or…
HUTCHMEDAnnounces NDA Acceptance in China with Priority Review Status for ORPATHYSand TAGRISSOCombination in Lung Cancer Patients with MET amplification After Progression on First-Line EGFRInhibitorTherapy
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Jan. 02, 2025 (GLOBE…
European Commission approves RYBREVANT (amivantamab) in combination with LAZCLUZE (lazertinib) for the first-line treatment of patients with EGFR-mutated advanced non-small cell lung cancer
This multitargeted, chemotherapy-free combination demonstrated superiority over osimertinib monotherapy for the first-line…
Menarini Group and MEDSIR Present the Phase III Study ADELA: A New Therapeutic Strategy for Advanced Breast Cancer
ADELA, an international phase III study being conducted across multiple countries, combines…
DARZALEX (daratumumab) subcutaneous formulation shows 51 percent reduction in risk of progression to active multiple myeloma for patients with high-risk smouldering multiple myeloma
First subcutaneous anti-CD38 therapy to demonstrate potential to prevent end-organ damage, and…
Combination of Eflornithine and Lomustine Demonstrates Clinically Meaningful Improvements in Overall Survival (OS) and Progression Free Survival (PFS) in Patients with Recurrent Astrocytoma, IDH Mutant Grade 3
November 22, 2024 11:00 ET | Source: Orbus Therapeutics, Inc. – OS…
Intellia Announces First Clinical Evidence from Ongoing Phase 1 Study that Nexiguran Ziclumeran (nex-z), an In Vivo CRISPR/Cas9-Based Gene Editing Therapy, May Favorably Impact Disease Progression inTransthyretin (ATTR) Amyloidosis
Consistently rapid, deep and durable reduction in serum TTR accompanied by evidence…